{"id":"NCT00759109","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)","officialTitle":"Long-term Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation: a Multicenter Study of Hepatocellular Carcinoma Prevention in Patients Non-responders to Combined Therapy With Alpha Interferon + Ribavirin or Peginterferon Alpha + Ribavirin or to Interferon Monotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-03","primaryCompletion":"2009-11","completion":"2009-11","firstPosted":"2008-09-25","resultsPosted":"2011-04-18","lastUpdate":"2017-04-07"},"enrollment":150,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Carcinoma, Hepatocellular"],"interventions":[{"type":"BIOLOGICAL","name":"Peginterferon alfa-2b","otherNames":["PegIntron","Pegylated Alfa-2b","SCH 054031"]},{"type":"OTHER","name":"Observation (no treatment)","otherNames":[]}],"arms":[{"label":"Arm A - PegIntron","type":"EXPERIMENTAL"},{"label":"Arm B - Control","type":"OTHER"}],"summary":"This study aims to compare the role of peginterferon α-2b (50 μg/week) vs. control (no treatment) in the prevention of hepatocellular carcinoma, in adult patients with cirrhosis and initial signs of portal hypertension who did not respond to previous combined therapy with interferon alfa + ribavirin or peginterferon alfa + ribavirin or to interferon alfa monotherapy and with a high proliferation rate before entering the study. The duration of treatment will be 3 years, and the follow-up period will be 2 years.","primaryOutcome":{"measure":"Number of Participants With the Development of Hepatocellular Carcinoma (HCC)","timeFrame":"During 3 years of treatment and 2 years of follow-up","effectByArm":[{"arm":"Arm A - PegIntron","deltaMin":15,"sd":null},{"arm":"Arm B - Control","deltaMin":11,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":18},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":74},"commonTop":["ASTHENIA","INFLUENZA LIKE ILLNESS","HYPERTENSION","OEDEMA PERIPHERAL","HEADACHE"]}}